Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. Biomol Biomed. 2022;22(2):300-301. doi:10.17305/bjbms.2021.6419